DYADIC INTERNATIONAL INC Net Change in Cash
DYADIC INTERNATIONAL INC (DYAI) reported Net Change in Cash of -$2.87 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-12
- DYADIC INTERNATIONAL INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$697.77K.
- DYADIC INTERNATIONAL INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$1.44M, a 135.56% decline year-over-year.
- DYADIC INTERNATIONAL INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $4.05M, a 599.32% increase year-over-year.
- DYADIC INTERNATIONAL INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $579.82K.
- DYADIC INTERNATIONAL INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$653.25K.
- DYADIC INTERNATIONAL INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$8.28K, a 101.15% decline from fiscal 2023.
- DYADIC INTERNATIONAL INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $720.76K.
- DYADIC INTERNATIONAL INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$9.95M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$2.87M 10-Q · filed 2026-08-12 | ||||
| 2026-03-31 | -$697.77K 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | -$653.25K 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $649.04K 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | -$2.53M 10-Q · filed 2026-08-12 | ||||
| 2025-03-31 | -$1.44M 10-Q · filed 2026-05-13 | ||||
| 2024-12-31 | -$8.28K 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | -$593.41K 10-Q · filed 2025-11-12 | ||||
| 2024-06-30 | -$381.63K 10-Q · filed 2025-08-13 | ||||
| 2024-03-31 | $4.05M 10-Q · filed 2025-05-14 | ||||
| 2023-12-31 | $720.76K 10-K · filed 2025-03-26 | ||||
| 2023-09-30 | $1.61M 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | $47.32K 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | $579.82K 10-Q · filed 2024-05-14 | ||||
| 2022-12-31 | -$9.95M 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | -$9.01M 10-Q · filed 2023-11-08 | ||||
| 2022-06-30 | -$6.27M 10-Q · filed 2023-08-09 | ||||
| 2022-03-31 | -$3.33M 10-Q · filed 2023-05-10 | -$3.33B 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | -$4.89M 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | -$6.98M 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | -$6.62M 10-Q · filed 2022-08-10 | ||||
| 2021-03-31 | -$7.58B 10-Q · filed 2022-05-12 | -$7.58M 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $15.81M 10-K · filed 2022-03-29 | ||||
| 2020-09-30 | $17.04M 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | $6.96M 10-Q · filed 2021-08-12 | ||||
| 2020-03-31 | -$126.71K 10-Q · filed 2021-05-13 | ||||
| 2019-12-31 | $2.44M 10-K · filed 2021-03-30 | ||||
| 2019-09-30 | $2.28M 10-Q · filed 2020-11-12 | ||||
| 2019-06-30 | $2.40M 10-Q · filed 2020-08-13 | ||||
| 2019-03-31 | $1.59M 10-Q · filed 2020-05-14 | ||||
| 2018-12-31 | -$3.40M 10-K · filed 2020-03-30 | ||||
| 2018-09-30 | -$4.07M 10-Q · filed 2019-11-13 | ||||
| 2018-06-30 | -$2.57M 10-Q · filed 2019-08-13 | ||||
| 2018-03-31 | -$1.16M 10-Q · filed 2019-05-09 | ||||
| 2017-12-31 | -$8.47M 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |